Novo Nordisk AS

Pharmaceuticals
Denmark
Executive 1Lars Rebien Sorensen, Chief Executive Officer; | Chief Executive Officer;
Executive 2Kare Schultz, President; Chief Operating Officer | President; Chief Executive Officer
Earnings Per Share Growth (%)7.70%
Cost of Goods Sold (US$ Millions)$2,377
Current Liabilities (US$ Millions)$5,500
Total Assets (US$ Millions)$7,558
Long Term Debt (Millions)N/A
Return on Equity62.21%
Revenue (US$ Millions)$14,624
Total Company Assets$12,581
Revenue Growth (%)6.32%
Net Income (US$ Millions)$4,323
Earnings Per Share (US$)$1.64
Total Equity (US$ Millions)$6,578
Profit Margin (%)29.56%
Debt To Equity Ratio (%)N/A
Inventories (Millions)$1,854